Rituximab acts by targeting which cell surface molecule?

Unlock all questions

This demo includes only 20 questions. Upgrade to access hundreds of questions, flashcards, exam simulations, and disable ads.

Full question bankExam simulationsFlashcards
From $25.99Unlock all

Study for the NBME Immunology Test. Study with flashcards and multiple choice questions, each question includes hints and explanations. Prepare to excel!

Multiple Choice

Rituximab acts by targeting which cell surface molecule?

Explanation:
Rituximab targets CD20, a molecule on the surface of B cells. Binding CD20 marks these cells for destruction through several mechanisms—antibody-dependent cellular cytotoxicity, complement-mediated lysis, and direct induction of apoptosis. CD20 is present on B cells from early development through mature stages but not on stem cells or plasma cells, so B cells are depleted while existing plasma cells (which produce antibodies) are largely spared, allowing some recovery over time as new B cells form. The other candidates are associated with T cells or NK cells (CD3, CD28, CD56), not with B cells, so they’re not what rituximab targets.

Rituximab targets CD20, a molecule on the surface of B cells. Binding CD20 marks these cells for destruction through several mechanisms—antibody-dependent cellular cytotoxicity, complement-mediated lysis, and direct induction of apoptosis. CD20 is present on B cells from early development through mature stages but not on stem cells or plasma cells, so B cells are depleted while existing plasma cells (which produce antibodies) are largely spared, allowing some recovery over time as new B cells form. The other candidates are associated with T cells or NK cells (CD3, CD28, CD56), not with B cells, so they’re not what rituximab targets.

More Multiple Choice Questions
Subscribe

Get the latest from Passetra

You can unsubscribe at any time. Read our privacy policy